Dr. Vose to be inducted into Royal College of Physicians of Edinburgh

by Tom O'Connor, UNMC public relations | March 11, 2019

Image with caption: Julie Vose, M.D.

Julie Vose, M.D.

Julie Vose, M.D., chief of the division of oncology/hematology in the UNMC Department of Internal Medicine, has been elected a fellow in the Royal College of Physicians of Edinburgh (RCPE). She will be inducted into the RCPE at a formal ceremony in June.

The RCPE is a medical royal college in Scotland. It is one of three organizations that sets the specialty training standards for physicians in the United Kingdom. Founded in 1681, the college has more than 12,000 fellows and members worldwide.

"This is a great honor for Dr. Vose, as it is somewhat unusual for an American to be named a fellow in the college," said James Armitage, M.D., the Joe Shapiro Professor of Medicine in the division of oncology/hematology for UNMC/Nebraska Medicine. "To become a fellow, one has to be nominated and then elected by the college."

Dr. Vose, who is the Neumann M. and Mildred E. Harris Professor, received her medical degree from UNMC in 1984 and completed her residency in internal medicine, serving as chief resident, and a fellowship in hematology/oncology at UNMC. She also completed a sabbatical at Stanford University and earned an MBA in health administration from the University of Colorado Business School.

"I'm very honored to become a fellow in the Royal College of Physicians Edinburgh," Dr. Vose said. "I think it's important for our physician leaders to be involved in national and international organizations like this. It provides an excellent forum for academic exchange and also to get the word out about the quality programs we have here at UNMC/Nebraska Medicine and the Fred & Pamela Buffett Cancer Center."

Dr. Vose has focused her career on translational research for improvement in the therapy of non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL). She has been instrumental in evaluating novel therapies such as monoclonal antibodies, idiotype vaccine therapies, immunotherapy, pathway directed agents and stem cell transplantation.

She has been recognized for her NHL research on a national and international level through research awards and invited lectureships worldwide. In addition, her funding record and publications in NHL therapy and transplantation research have added substantially to the research and knowledge base for the therapy of lymphoma. In 2015-2016, she served as president of the American Society of Clinical Oncology (ASCO).

Comments

Fill out the following and your comment will post once it has been approved.

Name (Required)

Email (Required)

Thank you, your comment will appear below once it has been approved.

Krishna Gundabolu
March 11, 2019 at 7:07 PM

Congratulations, Dr. Vose! It’s a great honor.

Lisa Runco
March 11, 2019 at 7:12 AM

Congratulations Dr. Vose. This is a huge honor and so well deserved, as you clearly are a global leader in your field.

Bud Shaw
March 11, 2019 at 6:57 AM

Congratulations, Dr. Vose!